1006890-01-2

Basic information

• Product Name: 7-Methoxy-4-(3-pyridinyl)-6-[2-(2-quinolinyl)ethoxy]quinazoline
• Synonyms: 7-Methoxy-4-(3-pyridinyl)-6-[2-(2-quinolinyl)ethoxy]quinazoline;7-Methoxy-4-(pyridin-3-yl)-6-[2-(quinolin-2-yl)ethoxy]quinazoline
• CAS NO: 1006890-01-2
• Molecular Formula: C25H20N4O2
• Molecular Weight: 408.4519
• Product Categories: Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 1006890-01-2.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 7-Methoxy-4-(3-pyridinyl)-6-[2-(2-quinolinyl)ethoxy]quinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Methoxy-4-(3-pyridinyl)-6-[2-(2-quinolinyl)ethoxy]quinazoline(1006890-01-2)
• EPA Substance Registry System: 7-Methoxy-4-(3-pyridinyl)-6-[2-(2-quinolinyl)ethoxy]quinazoline(1006890-01-2)

Safety Data

• Hazardous Substances Data: 1006890-01-2(Hazardous Substances Data)

Usage

Uses

7-Methoxy-4-(pyridin-3-yl)-6-[2-(quinolin-2-yl)ethoxy]quinazoline is a potent and selective compound in the phosphodiesterase 10A (PDE10A) inhibitor lead series for schizophrenia therapy.

Upstream product

• 286371-64-0 6-(benzyloxy)-7-methoxyquinazolin-4(3H)-one 
• 286371-65-1 6-(benzyloxy)-4-chloro-7-methoxyquinazoline 
• 4998-07-6 4,5-dimethoxy-2-nitro-benzoic acid 
• 31839-20-0 5-hydroxy-4-methoxy-2-nitrobenzoic acid 
• 52249-48-6 quinoline-2-acetic acid methyl ester 
• 1006889-93-5 6-(benzyloxy)-7-methoxy-4-(pyridin-3-yl)quinazoline 
• 855793-63-4 methyl 2-amino-5-(benzyloxy)-4-methoxybenzoate 
• 909912-09-0 benzyl 2-amino-5-(benzyloxy)-4-methoxybenzoic acid 
• 215659-03-3 methyl 5-hydroxy-4-methoxy-2-nitrobenzoate 
• 1011-50-3 2-quinolin-2-yl-ethanol 
• 1006889-97-9 7-methoxy-4-(pyridin-3-yl)quinazolin-6-ol 
• 164161-49-3 methyl 5-(benzyloxy)-4-methoxy-2-nitrobenzoate 

Relevant articles and documents

Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia

Utilizing structure-based virtual library design and scoring, a novel chimeric series of phosphodiesterase 10A (PDE10A) inhibitors was discovered by synergizing binding site interactions and ADME properties of two chemotypes. Virtual libraries were docked and scored for potential binding ability, followed by visual inspection to prioritize analogs for parallel and directed synthesis. The process yielded highly potent and selective compounds such as 16. New X-ray cocrystal structures enabled rational design of substituents that resulted in the successful optimization of physical properties to produce in vivo activity and to modulate microsomal clearance and permeability.